It is found that cdk12 inhibitor can effectively treat fatal Ewing's sarcoma in children

Ewing's sarcoma is the second most common bone cancer in children and adolescents, Recently, published in the latest issue of cancer cell, researchers from Dana Farber / Boston Children's cancer and blood disease research center found that cdk12 inhibitor can effectively treat children's fatal Ewing's sarcoma by testing the antitumor effect of a series of CDK inhibitors targeting Cdk7 / 12 / 13 protein The researchers said the study also found that cdk12 inhibitors can be combined with other drugs (http:// such as PARP inhibitors, to enhance the killing effect on cancer cells It is also found that inhibition of cdk12 expression can inhibit tumor growth In mouse models, the researchers found that cdk12 inhibitors significantly reduced tumor growth and prolonged the life of mice inoculated with tumors In this study, the researchers combined CDK12 and PARP inhibitors to stimulate Ewing's sarcoma, and the results showed that the combination therapy could significantly reduce the severity of the disease In addition, the researchers also found that cdk12 inhibitors can always regulate the gene activity of DNA damage.